Biophage, Inc.

Home · About Us · Mission & Vision · The Science · Pipeline · Team · Contact · Investors

A sleek stainless-steel bioreactor vessel labeled “Biophage, Inc.” standing on a spotless white lab bench, surrounded by neatly arranged glass flasks filled with pale amber bacterial cultures, each marked with livestock pathogen strain codes. In the background, refrigerated incubators and a large digital screen display a crisp, blue-toned schematic of a bacteriophage attacking bacteria. Cool, even overhead laboratory lighting reflects subtly off metal and glass, creating a professional, clinical atmosphere. Captured at eye level with photographic realism and moderate depth of field so the bioreactor and screen are in sharp focus while the distant lab equipment softens, the composition emphasizes innovation and precision in veterinary bacteriophage therapy.

Equine Phage

Bacteriophages — viruses that infect and kill bacteria — are among the most abundant and precisely targeted biological agents on Earth. Biophage harnesses them as living, self-limiting therapeutics that eliminate the specific pathogens driving disease in horses, livestock, and farmed fish, without the collateral damage of broad-spectrum antibiotics.

Bacteriophages

A phage recognizes and binds only its target bacterium, injects its genome, replicates inside the cell, and bursts it — then moves on to the next target and stops once the infection clears. This mechanism gives phage therapy three advantages antibiotics cannot match: precision (only the pathogen is killed, so the animal’s protective microbiome stays intact), activity against resistant strains (phages kill bacteria regardless of antibiotic resistance, directly addressing antimicrobial resistance), and no drug residues in meat, milk, or seafood, a critical requirement for food-animal and aquaculture markets. Our lead program targets Streptococcus equi, the cause of strangles — the most prevalent and economically damaging infectious disease in horses worldwide — with additional livestock and aquaculture programs (including Aeromonas and Streptococcus pathogens in farmed fish) following the same platform.

Explore our pipeline
A meticulously organized regulatory strategy workspace, featuring a large, matte-white desk with a slim laptop displaying an EPA and FDA submission dashboard filled with clean charts and timelines. Beside it lie neatly stacked briefing binders labeled “EPA Biopesticide Dossier” and “FDA Veterinary Biologic,” along with color-coded sticky-note tabs and a polished steel pen. In the background, a glass wall reveals frosted icons of bacteriophages and livestock silhouettes. Soft, diffused daylight from a nearby window mixes with cool overhead office lighting, eliminating harsh shadows and creating a calm, focused atmosphere. Shot from a slightly elevated angle in photographic realism with sharp focus throughout, the composition communicates investor-ready regulatory planning and disciplined biotech operations.

Why phages, why now

Antimicrobial resistance is accelerating while few new antibiotics reach the market, and regulatory pathways for phage-based products are actively opening at both the EPA and FDA. Biophage was built by clinicians who have managed these infections firsthand to move targeted, field-deployable phage therapies from discovery to the paddock.

Next: Pipeline →
Next: Pipeline →
Next: Pipeline →